Showing results (61-70 of 223) with videos related to

Sort By:
Pageof 23
Pediatric Blood & Cancer|April 23, 2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Dusica Babovic-Vuksanovic, Eva Dombi, et al.
The Oncologist|November 2, 2011
Clinical development of VEGF signaling pathway inhibitors in childhood solid tumorsJulia Glade Bender, Darrell J Yamashiro, Elizabeth Fox
Pediatric Blood & Cancer|July 11, 2023
Children's Oncology Group's 2023 blueprint for research: Developmental therapeuticsElizabeth Fox, D Williams Parsons, Brenda J Weigel, et al.
Developmental Neurobiology|August 23, 2012
Maternal and fetal antibrain antibodies in development and diseaseElizabeth Fox, David Amaral, Judy Van de Water
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Pharmacokinetics of intrathecal gemcitabine in nonhuman primatesMerrill J Egorin, Eleanor G Zuhowski, Cynthia M McCully, et al.
Pediatric Blood & Cancer|February 16, 2019
Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal functionPeter C Adamson, Gareth J Veal, Richard B Womer, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Towards Sonomyography-Based Real-Time Control of Powered Prosthesis Grasp SynergiesKeshav Bimbraw, Elizabeth Fox, Gil Weinberg, et al.
BMJ Case Reports|August 18, 2018
Small bowel adenocarcinoma in a patient with Lynch syndromeJessica Prince, Elizabeth Fox, Daniel Hancu, et al.
Cancer|April 1, 2005
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysSen H Zhuang, Manish Agrawal, Maureen Edgerly, et al.
Pageof 23